Negotiation Timeline

  • Initiation

    A drug is identified and brought into a pCPA process (see standard negotiation process or expedited negotiation pathways).

  • Consideration

    The pCPA considers the evidence (including HTA reimbursement recommendations) and gathers other data to inform the negotiation approach, in alignment with the needs of public drug plans. This phase concludes when the pCPA sends a letter of engagement to the manufacturer. 

    Letter of engagement sent to manufacturer

    This lets the manufacturer know the pCPA is ready to start negotiating.

  • Negotiation

    The pCPA negotiation team reaches out to the manufacturer to outline next steps, then we exchange offers to try to reach an agreement on terms and funding conditions.

  • Completion

    The pCPA creates a letter of intent outlining negotiated terms. If the negotiation ended without an agreement, the pCPA sends a letter letting the manufacturer know that the negotiation is closed. 

    Negotiation process concluded

Related negotiations

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

In combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Last updated:

November 15, 2024

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

as monotherapy for the adjuvant treatment of adult patients with Stage IB (T2a 4 cm), II, or IIIA NSCLC, and with PD-L1 tumor proportion score (TPS) less than 50% who have undergone complete resection and platinum-based chemotherapy.

Last updated:

February 20, 2025

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

As monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors

Last updated:

February 20, 2025

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

In combination with enfortumab vedotin, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.

Last updated:

May 26, 2025